Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$5.42
-0.5%
$5.42
$4.41
$8.69
$2.04B0.421.91 million shs1.04 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$10.80
-4.7%
$8.39
$1.16
$12.48
$648.76M0.02983,810 shs655,216 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.16
-3.6%
$8.99
$6.23
$16.44
$2.08B0.933.01 million shs2.37 million shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$20.59
+1.3%
$20.34
$15.96
$44.34
$2.31B0.85795,408 shs903,109 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-0.60%-6.11%-5.79%-9.54%+18.64%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-4.68%-5.01%+24.86%+90.48%+823.08%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-3.58%-5.08%+2.81%+3.15%+32.18%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
+1.28%+10.70%-11.44%+2.80%-26.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$5.42
-0.5%
$5.42
$4.41
$8.69
$2.04B0.421.91 million shs1.04 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$10.80
-4.7%
$8.39
$1.16
$12.48
$648.76M0.02983,810 shs655,216 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.16
-3.6%
$8.99
$6.23
$16.44
$2.08B0.933.01 million shs2.37 million shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$20.59
+1.3%
$20.34
$15.96
$44.34
$2.31B0.85795,408 shs903,109 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-0.60%-6.11%-5.79%-9.54%+18.64%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-4.68%-5.01%+24.86%+90.48%+823.08%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-3.58%-5.08%+2.81%+3.15%+32.18%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
+1.28%+10.70%-11.44%+2.80%-26.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.80
Reduce$8.0047.55% Upside
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.08
Buy$20.3087.96% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.79
Moderate Buy$23.78159.58% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.63
Moderate Buy$45.83122.60% Upside

Current Analyst Ratings Breakdown

Latest CLYM, BHC, OCUL, and ZLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Boost Price TargetBuy$15.00 ➝ $20.00
5/11/2026
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
DowngradeSell (D-)Sell (E+)
5/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Boost Price TargetOutperform$15.00 ➝ $17.00
5/8/2026
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Lower Price TargetBuy$47.00 ➝ $44.00
5/6/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Set Price Target$21.00
5/6/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Boost Price TargetBuy$8.00 ➝ $19.00
5/6/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingOutperform$30.00
5/5/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Initiated CoverageBuy$22.00
5/5/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Reiterated RatingBuy$18.00
5/4/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
DowngradeSell (D)Sell (D-)
4/27/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Lower Price TargetSector Perform$10.00 ➝ $9.00
(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$10.27B0.20$7.23 per share0.75($2.89) per share-1.88
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$2.59 per shareN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$51.95M38.61N/AN/A$2.66 per share3.44
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$460.16M5.07N/AN/A$5.84 per share3.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$157M-$3.24N/A1.42N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%N/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%N/A

Latest CLYM, BHC, OCUL, and ZLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.26-$0.20+$0.06-$0.20N/AN/A
5/7/2026Q1 2026
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million
4/29/2026Q1 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion
4/1/2026Q1 2026
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A-$0.50N/A-$0.50N/A$99.61 million
3/5/2026Q4 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.20-$0.26-$0.06-$0.26N/AN/A
2/26/2026Q4 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.44-$0.46-$0.02-$0.50$122.67 million$127.60 million
2/18/2026Q4 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$1.21$1.08-$0.13-$0.30$2.71 billion$2.78 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
54.68
1.32
0.97
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
27.86
27.86
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.12
14.81
14.73
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
2.40
2.19

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20.67%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.60%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.30%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,300373.81 million296.55 millionOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
957.26 million55.77 millionN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230218.96 million213.92 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,784113.41 million107.88 millionOptionable

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares
Zai Lab (NASDAQ:ZLAB) Downgraded by Wall Street Zen to Sell
Zai Lab Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$5.42 -0.03 (-0.51%)
Closing price 05/15/2026 03:59 PM Eastern
Extended Trading
$5.48 +0.05 (+0.98%)
As of 05/15/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$10.80 -0.53 (-4.68%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$11.15 +0.35 (+3.23%)
As of 05/15/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$9.16 -0.34 (-3.58%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$9.19 +0.03 (+0.32%)
As of 05/15/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$20.59 +0.26 (+1.28%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$20.56 -0.03 (-0.15%)
As of 05/15/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.